Specialty APIs Supplier | cGMP Active Pharmaceutical Ingredients & DMF Support

 

Commercial and pilot-scale APIs manufactured under cGMP guidelines with complete regulatory documentation for global submission.

 

 
 
Category Introduction

 

Specialty Active Pharmaceutical Ingredients require tight solid-state controls, validated purification steps, and explicit organic/inorganic impurity profiles. This product group includes small-molecule APIs applied in cardiovascular, antiviral, and diagnostic imaging formulations.

 

Production takes place in dedicated reactor lines complying with cGMP standards. Process control includes particle size reduction, polymorphism monitoring via XRD, and residual solvent removal to limits below ICH Q3C threshold levels.

 

Product Portfolio
 

Product Name

CAS Number

Main Therapeutic Class

Purity (HPLC)

Key Specification Controls

Regulatory Status

Rosuvastatin Calcium

147098-20-2

Cardiovascular

≥ 99.0%

Enantiomeric impurity ≤ 0.10%, $D_{90} < 20\,\mu\text{m}$

USDMF / CEP / EU-GMP

Ranolazine

95635-55-5

Anti-anginal

≥ 99.5%

Total impurities ≤ 0.50%, Individual unknown ≤ 0.05%

USDMF / EU-GMP

Tenofovir Disoproxil Fumarate

202138-50-9

Antiviral

≥ 98.5%

Form I crystalline purity, Genotoxic impurity screen

USDMF / CEP

Atazanavir Sulfate

229975-97-7

Antiretroviral

≥ 99.0%

Diastereomer balance, Residual solvents (Ethanol/Acetone)

USDMF

Etoricoxib

202409-33-4

Selective COX-2 Inhibitor

≥ 99.5%

Single specified impurity ≤ 0.10%, Heavy metals ≤ 10 ppm

USDMF / EU-GMP

Iopamidol

60166-93-0

X-ray Contrast Agent

≥ 98.5%

Free iodine ≤ 10 ppm, Bacterial endotoxins < 0.5 EU/mg

USDMF / CEP / cGMP

 

Nintedanib Esylate

 

Product Information

Batch release testing follows USP, EP, and ChP monograph requirements. Specifications cover key chemical, physical, and analytical attributes required for solid oral and parenteral dosage formulations:

 

Assay & Impurity Profile: HPLC assay limits set at 98.5%–100.5% (dried basis). Impurity profiling tracks synthesis-related substances and degradation products according to ICH Q3A/B guidelines, with single unknown impurities capped at ≤ 0.05%.

 

Particle Size Distribution (PSD): Controlled via air-jet micronization or mechanical milling. Customized targets available down to D90 < 10 μm or defined ranges (D10, D50, D90) verified by laser diffraction particle size analysis.

 

Polymorph Verification: X-ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) confirm crystal structure stability and phase identity across production lots.

 

Solvents & Elemental Impurities: Headspace Gas Chromatography (GC-HS) quantifies Class 1, Class 2, and Class 3 residual solvents. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) tests for heavy metal limits aligned with ICH Q3D options 1 or 2.

 

Product & Supply Status

 
 
01
 

Production Scale

Multi-ton commercial production lines operating alongside kilogram-scale equipment for clinical and pilot-batch orders.

 
02
 

Packaging Solutions

Primary packaging consists of double food/pharma-grade polyethylene bags inside heat-sealed aluminum foil bags, enclosed in outer HDPE drums. Nitrogen flushing and light-protective options available based on stability profile requirements.

 
03
 

Evaluation Samples

10g to 100g verification samples supplied with full lot-specific Certificate of Analysis (COA) for incoming inspection and laboratory testing.

Olaparib

 

Manufacturing & Technical Capabilities

Reaction Vessels

Glass-lined and stainless steel reactors ranging from 500 L to 5,000 L operating at temperature ranges from -78 °C to 200 °C.

Core Reactions

Asymmetric synthesis, catalytic hydrogenation, optical resolution, halogenation, and controlled crystallization.

Cleanroom Operations

Class 100,000 (ISO 8) cleanrooms dedicated to drying, milling, sieving, and packaging operations. Equipment includes agitated nutsche filter-dryers, fluid bed dryers, and micronizers.

Analytical Instrument Control

In-house testing laboratory equipped with HPLC-UV/CAD, GC-FID/HS, ICP-MS, FTIR, Karl Fischer titrators, and laser particle size analyzers.

 

 

Sorafenib Tosylate

 

Quality & Regulatory Information

GMP Compliance: Quality system configured in accordance with ICH Q7 guidelines for active pharmaceutical ingredients.

 

Regulatory Submissions: Drug Master Files (USDMF, CEP/EDMF) maintained in eCTD format. Letters of Access (LOA) generated upon customer registration and commercial verification.

 

Stability Testing: Real-time stability testing (25 °C ± 2 °C / 60% ± 5% RH) and accelerated stability testing (40 °C ± 2 °C / 75% ± 5% RH) conducted according to ICH Q1A(R2) protocols.

 

Audits: Customer quality audits and regulatory inspections accommodated with full access to batch production records, analytical raw data, and cleaning validation protocols.

 

 

Procurement Information

Documentation Support: Every batch shipment includes COA, SDS, Method of Analysis (MOA), Process Flow Diagram, and TSE/BSE Non-Use Statements. Nitrosamine and Elemental Impurity Risk Assessment reports available upon request.

 

Minimum Order Quantity (MOQ): Pilot orders starting at 1 kg–5 kg; standard commercial order MOQ is 25 kg.

 

Lead Time: 2–3 weeks for stock items; 4–6 weeks for custom micronization or scheduled batch production.

 

Shipping Conditions: Ambient, chilled (2 °C–8 °C), or frozen storage/transit packaging matching specific product stability profiles.

Nintedanib Esylate

 

 

FAQ

 

Q: What documentation is available for regulatory filing support?

A: eCTD-formatted USDMFs, CEPs, and open-part DMF dossiers are available, along with LOA issuance, process flow charts, and impurity evaluation summaries.

Q: How are particle size requirements handled for specific dosage forms?

A: Micronization parameters are adjusted based on target D90 specifications. Laser diffraction testing provides particle distribution curves for each milled batch.

Q: Are elemental impurity and residual solvent reports included with batch releases?

A: Yes, batch COAs report quantitative values for residual solvents via GC-HS and elemental impurities via ICP-MS in compliance with ICH Q3C and Q3D guidelines.

Q: What stability data exists to support retest periods?

A: Retest periods are backed by ongoing real-time stability protocols (25 °C/60% RH) and accelerated testing (40 °C/75% RH) per ICH Q1A(R2) standards.

Q: What is the process for requesting a factory or quality audit?

A: Quality audits are scheduled after executing a Non-Disclosure Agreement (NDA) and completing preliminary vendor qualification documentation.

 

Request Technical Documentation & Pricing

 

Submit your specification requirements, target volume, and required regulatory filings. Our technical and regulatory support team responds within 24 business hours.

 

[ Request Commercial Quote ] [Talk to Our Technical Team]

 

We're professional specialty apis manufacturers and suppliers in China, specialized in supplying high quality products and service. We warmly welcome you to buy high-grade specialty apis at competitive price from our factory.

api for e commerce, Methocarbamol, Potassium Guaiacol Sulfonate
Send Inquiry